Eli Lilly and GSK-backed precision oncology drug developer Turning Point Therapeutics floated at the top of its range while expanding the number of shares it issued.

US-based oncology therapy developer Turning Point Therapeutics raised approximately $167m from an initial public offering today that gave exits to pharmaceutical firms GlaxoSmithKline (GSK) and Eli Lilly.

The IPO consisted of 9.25 million shares issued on the Nasdaq Global Market and priced at $18.00 each. The company had set a $16 to $18 range earlier this week, and had initially planned to sell just over 8.8 million shares.

Turning Point is developing precision small molecule cancer drugs intended to address…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn